US Stock Market Movement: Eli Lilly Plunges on September 30 as Novo Nordisk Outperforms and Healthcare Sector Weakens

Eli Lilly September 30 Drop Analysis

Keywords: Novo Nordisk data advantage, weakening healthcare sector

1. On September 30, 2026, Novo Nordisk published real-world research indicating that patients who increased their Ozempic dosage had a lower risk of major adverse cardiovascular events compared to those who switched to Eli Lilly's Mounjaro, intensifying competitive data pressure among similar drugs.

2. On September 30, 2026, the healthcare sector weakened, with the New York Stock Exchange Healthcare Index falling by about 0.3% to 0.4%, causing Eli Lilly's share price to come under pressure along with the sector.

3. On September 30, 2026, following Eli Lilly's positive trial results for EloraTZP, its share price once rose by 2.6%, but the gain narrowed to around 0.5%. Short-term volatility increased as gains were given back after the positive news was priced in.

(Disclaimer: This content is collected and summarized from public information by AI technology and is for reference only. It does not constitute investment advice.)